Bayer's near-approval Farxiga rival meets goal in 2nd phase 3

Bayer’s finerenone has met the primary endpoint in another phase 3 clinical trial. The study, which linked the mineralocorticoid receptor antagonist to a significant reduction over placebo against a composite cardiovascular event endpoint, has met the primary endpoint in another phase 3 clinical trial.